MX2023011441A - Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico. - Google Patents
Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico.Info
- Publication number
- MX2023011441A MX2023011441A MX2023011441A MX2023011441A MX2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A
- Authority
- MX
- Mexico
- Prior art keywords
- pi3k
- treatment
- pancreatic cancer
- delta inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104416.9A GB202104416D0 (en) | 2021-03-29 | 2021-03-29 | Treatment reginmens |
| GBGB2108242.5A GB202108242D0 (en) | 2021-06-09 | 2021-06-09 | Methods of treatment |
| GBGB2117511.2A GB202117511D0 (en) | 2021-12-03 | 2021-12-03 | Treatment regimens |
| PCT/EP2022/058296 WO2022207648A1 (en) | 2021-03-29 | 2022-03-29 | A pi3k-delta inhibitor for the treatment of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011441A true MX2023011441A (es) | 2023-10-18 |
Family
ID=81388891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011441A MX2023011441A (es) | 2021-03-29 | 2022-03-29 | Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240216385A1 (https=) |
| EP (1) | EP4313059A1 (https=) |
| JP (1) | JP2024511836A (https=) |
| AU (1) | AU2022250707B2 (https=) |
| CA (1) | CA3212522A1 (https=) |
| MX (1) | MX2023011441A (https=) |
| WO (1) | WO2022207648A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202108245D0 (en) * | 2021-06-09 | 2021-07-21 | Ionctura Sa | Methods of treatment |
| GB202308807D0 (en) * | 2023-06-13 | 2023-07-26 | Ionctura Sa | Combinations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201290305A1 (ru) * | 2009-11-13 | 2012-12-28 | Мерк Сероно С.А. | Производные трициклического пиразоламина |
| WO2014121901A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Polymorphic forms |
| US9986723B2 (en) * | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| GB201502020D0 (en) * | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| EP3610264A1 (en) * | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
-
2022
- 2022-03-29 JP JP2023560325A patent/JP2024511836A/ja active Pending
- 2022-03-29 WO PCT/EP2022/058296 patent/WO2022207648A1/en not_active Ceased
- 2022-03-29 AU AU2022250707A patent/AU2022250707B2/en active Active
- 2022-03-29 MX MX2023011441A patent/MX2023011441A/es unknown
- 2022-03-29 EP EP22719273.9A patent/EP4313059A1/en active Pending
- 2022-03-29 CA CA3212522A patent/CA3212522A1/en active Pending
- 2022-03-29 US US18/553,333 patent/US20240216385A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022250707B2 (en) | 2026-04-09 |
| WO2022207648A1 (en) | 2022-10-06 |
| US20240216385A1 (en) | 2024-07-04 |
| AU2022250707A1 (en) | 2023-10-12 |
| CA3212522A1 (en) | 2022-10-06 |
| JP2024511836A (ja) | 2024-03-15 |
| EP4313059A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20240210A1 (ar) | مثبطات kras | |
| ZA202309638B (en) | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof | |
| JOP20220142A1 (ar) | مثبطات kras g12c | |
| MX2022014104A (es) | Inhibidores de atr para el tratamiento del cancer. | |
| AU2019310335A8 (en) | Methods of treating cancer with PI3K inhibitor, GDC-0077 | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| WO2020191056A8 (en) | Pyridazinones and methods of use thereof | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| MX2023012095A (es) | Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada. | |
| WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| MX2023011441A (es) | Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico. | |
| MX2010004967A (es) | Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| ZA202103914B (en) | Cxcr7 inhibitors for the treatment of cancer | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| PH12022550254A1 (en) | MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF |